[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.114.118. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 2, 1999

Glycemic Control and Quality of Life in Patients With Type 2 Diabetes—Reply

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(21):1985-1986. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602

In Reply: Dr Adelman correctly notes that the QOL treatment differences observed between the placebo and glipizide gastrointestinal therapeutic system groups primarily were due to the worsening of QOL in patients receiving placebo and questions whether this finding might be due to a discrepancy in the number of newly diagnosed patients between the 2 groups. This is unlikely, since only patients with an established diagnosis of diabetes who were treated with either diet or sulfonylurea for at least 3 months were included in the study.

First Page Preview View Large
First page PDF preview
First page PDF preview
×